

Supplementary Table 1.

	MS (n=20)	HC (n=10)	<i>p</i> - value
Age , mean years± SD (range)	40.35±8.44 [27-57]	35.2±9.8 [25-61]	p=0.146
Females , n (%)	15 (75)	6 (60)	p=0.431
Relapsing Remitting MS , n (%)	21(100)	-	
Vaccine type			
Pfizer, n (%)	12 (61.9)	8 (80)	p=0.419
Moderna, n (%)	8 (38.1)	2 (20)	
Time from last aCD20 to first vaccine (weeks) , mean±SD [range]	19.77±9.52 [2.6-41.1]	-	
Prior cycles of aCD20 , mean±SD [range]	3.2±1.6 [1-7]	-	
Type of aCD20			
Ocrelizumab, n (%)	19 (95)	-	
Rituximab, n (%)	1 (5)	-	
EDSS , mean±SD [range]	1.5±2.2 (0-6.5)	-	

Supplementary Table 1. MS-aCD20 and HC cohort Demographics.

Supplementary Table 2.

	HC	MS-αCD20	<i>p</i> - value
anti-Spike IgG			
T2	100%	28.57%	0.0006
T3	100%	29.41%	0.0004
T4	100%	82.35%	0.2735
T5	100%	88.89%	0.5238
RBD Protein IgG			
T2	60%	7.14%	0.0088
T3	100%	17.65%	<0.0001
T4	100%	41.48%	0.0031
T5	100%	50%	0.0098

Supplementary Table 2. Anti-Spike and anti-RBD IgG serological positivity rates in HC and MS- α CD20 patients across different time points. Two-sided Fisher's exact test.

Supplementary Table 3.

Antigen-specific memory B cells	Timepoint	Comparison	p - value	method
Spike ⁺	T2	HC vs MS-aCD20	9.20E-06	Wilcoxon
Spike ⁺	T3	HC vs MS-aCD20	1.10E-05	Wilcoxon
Spike ⁺	T4	HC vs MS-aCD20	2.60E-05	Wilcoxon
Spike ⁺	T5	HC vs MS-aCD20	1.10E-05	Wilcoxon
RBD ⁺	T2	HC vs MS-aCD20	5.50E-06	Wilcoxon
RBD ⁺	T3	HC vs MS-aCD20	3.30E-06	Wilcoxon
RBD ⁺	T4	HC vs MS-aCD20	1.50E-05	Wilcoxon
RBD ⁺	T5	HC vs MS-aCD20	8.70E-06	Wilcoxon

Supplementary Table 3. The frequencies of Spike⁺ and RBD⁺ antigen-specific memory B cells were compared between HC and MS-aCD20 groups at each timepoint. Wilcoxon signed-rank testing was used, and the *p* values are shown.


Supplementary Table 4.

Antibody reactivity	Fluorochrome Conjugation	Clone	Supplier	Catalog #
CD27	BUV 395	L128	BD	563815
CD71	BUV 496	M-A712	BD	750652
CD3	BUV 563	UCHT1	BD	748569
CD8	BUV 615	RPA-T8	BD	751518
CD38	BUV 661	HIT2	BD	612969
CCR6	BUV 737	11A9	BD	612780
HLA-DR	BUV 805	G46-6	BD	748338
CTLA4	BV 421	BNI3	BD	562743
PD-1	BV 480	EH12.11	BD	566112
CCR7	BV 510	G043H7	Biolegend	353232
Zombie Yellow	BV 570	-	Biolegend	423103
CD45RA	BV 605	HI100	Biolegend	304134
CD25	BV 650	M-A251	BD	563719
CXCR3	BV 711	G025H7	Biolegend	353732
CD4	BV 750	SK3	BD	566355
ICOS	BV 785	C398.4A	Biolegend	313534
SLAM	AF 488	A12 (7D4)	Biolegend	306312
CD127	BB 700	HIL-7R-M21	BD	566398
CXCR4	PE-Cy5	12G5	Biolegend	306508
FoxP3	PE-Cy5.5	PCH101	Fisher	35-4776-42
Ki67	PE-Cy7	B56	BD	561283
T-bet	AF 647	4B10	Biolegend	644804
CXCR5	APC-R700	RF8B2	BD	565191
Bcl-6	APC-Cy7	K112-91	BD	563581


Supplementary Table 4. Antibody specifications used for FACS-based high-dimensional analysis.

Extended Data Figure 1.


A




B




C




D




Extended Data Figure 2.




A




B




C




D




E




Extended Data Figure 4.

A**B**

Metacluster 3




A



B

CD4+ AIM+ (CD200 & CD40L)

CD8+ AIM+ (IFN γ & 41BB)




C

Healthy total non-naïve CD4+


Healthy total non-naïve CD4+

MS-aCD20 total non-naïve CD4+

MS-aCD20 total non-naïve CD4+



AIM+ Th1




D

Healthy total non-naïve CD4+


Healthy total non-naïve CD4+

MS-aCD20 total non-naïve CD4+


MS-aCD20 total non-naïve CD4+



AIM+ Tfh




Extended Data Figure 6.




Extended Data Figure 7.


Healthy total non-naïve CD8+




Healthy total non-naïve CD8+



MS-aCD20 total non-naïve CD8+




MS-aCD20 total non-naïve CD8+



Extended Data Figure 8.

A



B

